Skip to main content
梓橦宫 logo

梓橦宫 — Investor Relations & Filings

Ticker · 920566 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 625 across all filing types
Latest filing 2024-09-25 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920566

About 梓橦宫

http://www.zitonggong.com/

Zitonggong specializes in the research, development, and production of specialized therapeutic agents. Established with a heritage dating back to 1780, the company holds a recognized heritage brand designation. Its primary product portfolio centers on neurological and cerebrovascular health, featuring Oxiracetam in various dosage forms for treating cognitive dysfunction and brain injuries. The company also develops treatments for digestive health, including Compound Aloe Capsules, and produces artificial Oriental Bezoar. Operations are centered on integrating traditional medicinal knowledge with modern chemical synthesis and manufacturing standards. The company maintains a focus on clinical efficacy and technological advancement in the fields of neurology and gastroenterology.

Recent filings

Filing Released Lang Actions
2023年股权激励计划限制性股票预留授予结果公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the results of a 2023 equity incentive plan involving restricted stock grants. It details the number of shares granted, the recipients, the terms of the stock restrictions, and the performance conditions for lifting the restrictions. It also includes information about the stock source, the lock-up periods, and the verification of funds received. There is no indication that this is a full financial report, audit report, or earnings release. It is not a regulatory filing or a report publication announcement since it contains substantive details about the equity incentive grant. The document is focused on capital structure changes related to stock grants and share repurchases for the incentive plan. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-09-25 Chinese
第四届董事会第八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the eighth meeting of the fourth board of directors of Sichuan Zitonggong Pharmaceutical Co., Ltd. It details the meeting's attendance, the agenda items discussed, voting results, and procedural compliance. The content focuses on board decisions, such as approval of using idle funds for financial products and scheduling a shareholders' meeting. There is no financial data, earnings information, or detailed report content. The document is not a full report but a board meeting resolution announcement, fitting the category of Board/Management Information (MANG). The document length is short (1238 characters), and it is not an announcement of a report publication but a substantive board meeting resolution notice.
2024-09-25 Chinese
2024年第三次临时股东大会通知公告（提供网络投票）
Regulatory Filings Classification · 95% confidence The document is a notice for the 2024 third extraordinary general meeting of shareholders (临时股东大会) of Sichuan Zitonggong Pharmaceutical Co., Ltd. It details the meeting date, voting methods (including online voting), eligibility, agenda items, and registration procedures. It is not a report of financial results or an annual/interim report, nor is it a transcript or audit report. It is an official announcement about convening a shareholders meeting, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since it is a notice of the meeting itself (not the voting results or proxy materials), it is best classified as a Regulatory Filing (RNS) because it does not fit the other categories exactly and is a general regulatory announcement about the meeting. The document length is short (2167 characters), and it is an announcement, not a report or transcript. Therefore, the best classification is Regulatory Filings (RNS).
2024-09-25 Chinese
回购股份注销完成暨股份变动公告
Transaction in Own Shares Classification · 100% confidence The document is a formal announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the completion of share repurchase cancellation and the resulting changes in shareholding structure. It details the number of shares repurchased and cancelled, the updated share capital, and the changes in shareholding percentages. It also mentions the completion of related registration procedures and includes a confirmation certificate from the securities registration and settlement company. The document is short (1131 characters) and focuses on share repurchase and capital changes, not on financial results or management commentary. Therefore, it fits the category of a Transaction in Own Shares (POS) filing, which covers company buybacks and share cancellations.
2024-09-25 Chinese
关于子公司完成工商变更并换领营业执照的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a subsidiary's completion of business registration changes and issuance of a new business license. It details the increase in registered capital and introduction of strategic investors, along with the impact and risk warnings related to this change. There are no financial statements, audit information, or detailed financial data presented. The document is a corporate announcement about a capital increase and business registration update, which fits the category of Capital/Financing Update (CAP). The document length is short and it is not merely announcing a report publication, so it is not RPA. Therefore, the classification is CAP with high confidence.
2024-09-25 Chinese
关于使用自有闲置资金购买理财产品的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the use of idle funds to purchase financial products. It details the purpose, amount, decision-making process, risk analysis, and impact on the company. The document is relatively short (1578 characters) and does not contain financial statements or detailed financial data. It is an update on the company's financing or capital management activities, specifically about investing idle funds in low-risk financial products. This fits the category of Capital/Financing Update (CAP).
2024-09-25 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.